Redeye: Amniotics Q3 2023 - Rights Issue Foundation for Lung Transplantation Study
Redeye comments on Amniotics' Q3 report, including the rights issue and latest development with the main candidate PulmoStem.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/